Elsevier

L'Encéphale

Volume 42, Issue 1, Supplement 1, February 2016, Pages 1S12-1S23
L'Encéphale

Propriétés pharmacologiques de la vortioxetine et leurs conséquences pré-cliniquesPharmacological properties of vortioxetine and its pre-clinical consequences

https://doi.org/10.1016/S0013-7006(16)30015-XGet rights and content

Résumé

La vortioxetine (Brintellix®, 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine), un nouvel antidépresseur (AD) multimodal avec un mécanisme d'action innovant, a obtenu l'autorisation de mise sur le marché de la Food and Drug Administration (FDA) et de la European Medicines Agency (EMA) en 2013. La vortioxetine est présentée comme antidépresseur multimodal puisque c'est non seulement un inhibiteur du transporteur de la sérotonine (SERT), mais aussi un antagoniste des récepteurs sérotoninergiques 5-HT1D, 5-HT3, 5-HT7, un agoniste partiel des récepteurs 5-HT1B et un agoniste des récepteurs 5-HT1A. Son profil pharmacologique particulier lui permet à la fois de moduler les neurotransmissions sérotoninergiques et noradrenergiques centrales, mais aussi les systèmes histaminergiques, cholinergiques, GABAergiques et glutamatergiques. Ainsi, en plus de son activité antidépressive et anxiolytique, la vortioxetine semble apporter un réel bénéfice cognitif dans différents modèles animaux. La synthèse de ces données démontre que, même si des travaux complémentaires restent à réaliser, notamment dans le domaine de la réponse insuffisante à un 1er traitement antidépresseur, la vortioxetine représente d'ores et déjà une nouvelle option thérapeutique pour le traitement des épisodes dépressifs majeurs.

Summary

Selective Serotonin Reuptake Inhibitors (SSRIs) are extensively used for the treatment of major depressive disorder (MDD). SSRIs are defined as indirect receptor agonists since the activation of postsynaptic receptors is a consequence of an increase in extracellular concentrations of serotonin (5-HT) mediated by the blockade of serotonin transporter. The activation of some serotoninergic receptors (5-HT1A, post-synaptic, 5-HT1B post-synaptic, 5-HT2B, and 5-HT4), but not all (5-HT1A, pre-synaptic, 5-HT1B pre-synaptic, 5-HT2A, 5-HT2C, 5-HT3, and probably 5-HT6), induces anxiolytic/antidepressive – like effects. Targetting specifically some of them could potentially improve the onset of action and/or efficacy and/or prevent MD relapse. Vortioxetine (Brintellix®, 1- [2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a novel multi-target antidepressant drug approved by the Food and Drug Administration (FDA) and by European Medicines Agency. Its properties are markedly different from the extensively prescribed SSRIs. Compared to the SSRIs, vortioxetine is defined as a multimodal antidepressant drug since it is not only a serotonin reuptake inhibitor, but also a 5-HT1D, 5-HT3, 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist and 5-HT1A receptor agonist. This specific pharmacological profile enables vortioxetine to affect not only the serotoninergic and noradrenergic systems, but also the histaminergic, cholinergic, gamma-butyric acid (GABA) ergic and glutamatergic ones. Thus, vortioxetine not only induces antidepressant-like or anxiolytic-like activity but also improves cognitive parameters in several animal models. Indeed, vortioxetine was shown to improve working memory, episodic memory, cognitive flexibility and spatial memory in young adult rodents and also in old animal models. These specific effects of the vortioxetine are of interest considering that cognitive dysfunction is a common comorbidity to MDD. Altogether, even though this molecule still needs to be investigated further, especially in the insufficient-response to antidepressant drugs, vortioxetine is already an innovative therapeutic option for the treatment of major depression.

Références (86)

  • IA Pullar et al.

    The role of the 5-HT1D receptor as a presynaptic autoreceptor in the guinea pig

    European journal of pharmacology

    (2004)
  • CJ Peddie et al.

    A subpopulation of serotonin 1B receptors colocalize with the AMPA receptor subunit GluR2 in the hippocampal dentate gyrus

    Neuroscience letters

    (2010)
  • CJ Peddie et al.

    Dendritic colocalisation of serotonin1B receptors and the glutamate NMDA receptor subunit NR1 within the hippocampal dentate gyrus: an ultrastructural study

    Journal of chemical neuroanatomy

    (2008)
  • AJ Greenshaw

    Behavioural pharmacology of 5-HT3 receptor antagonists: a critical update on therapeutic potential

    Trends in pharmacological sciences

    (1993)
  • PB Hedlund et al.

    Functional, molecular and pharmacological advances in 5-HT7 receptor research

    Trends in pharmacological sciences

    (2004)
  • K Varnas et al.

    Distribution of 5-HT7 receptors in the human brain: a preliminary autoradiographic study using [3H] SB-269970

    Neuroscience letters

    (2004)
  • LL Fan et al.

    In vivo effect of 5-HT (7) receptor agonist on pyramidal neurons in medial frontal cortex of normal and 6-hydroxydopamine-lesioned rats: an electrophysiological study

    Neuroscience

    (2011)
  • K Tokarski et al.

    5-HT7 receptors increase the excitability of rat hippocampal CA1 pyramidal neurons

    Brain research

    (2003)
  • A Suwabe et al.

    Effect of a 5-HT (1A) receptor agonist, flesinoxan, on the extracellular noradrenaline level in the hippocampus and on the locomotor activity of rats

    Brain research

    (2000)
  • A Mork et al.

    Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats

    Pharmacology, biochemistry, and behavior

    (2013)
  • S Kim et al.

    Comparative analysis of the anxiety-related behaviors in four inbred mice

    Behavioural processes

    (2002)
  • JP Guilloux et al.

    Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice

    Neuropharmacology

    (2013)
  • DJ David et al.

    Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression

    Neuron

    (2009)
  • ID Neumann et al.

    Animal models of depression and anxiety: What do they tell us about human condition ?

    Progress in neuro-psychopharmacology & biological psychiatry

    (2011)
  • Y Li et al.

    Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats

    Behavioural brain research

    (2013)
  • I Mendez-David et al.

    Adult hippocampal neurogenesis: an actor in the antidepressant-like action

    Annales pharmaceutiques francaises

    (2013)
  • NEA Haddjeri et al.

    Effects of the multimodal antidepressant Lu AA21004 on rat synaptic and cellular hippocampal plasticity and memory recognition

    Eur Neuropsychopharmacol

    (2012)
  • R Malinow et al.

    LTP mechanisms: from silence to four-lane traffic

    Current opinion in neurobiology

    (2000)
  • E Basar et al.

    A review of brain oscillations in cognitive disorders and the role of neurotransmitters

    Brain research

    (2008)
  • L Westrich et al.

    Involvement of 5-HT (7) receptors in vortioxetine's modulation of circadian rhythms and episodic memory in rodents

    Neuropharmacology

    (2015)
  • JB Jensen et al.

    Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation

    Eur Neuropsychopharmacol

    (2014)
  • KG du Jardin et al.

    Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism

    Eur Neuropsychopharmacol

    (2014)
  • YSC Li et al.

    Memory impairment in old mice is differentially sensitive to different classes of antidepressants

    Eur Neuropsychopharmacol

    (2013)
  • D Marazziti et al.

    Cognitive impairment in major depression

    European journal of pharmacology

    (2010)
  • MH Trivedi et al.

    Cognitive dysfunction in unipolar depression: implications for treatment

    Journal of affective disorders

    (2014)
  • MJ Millan

    Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application

    Pharmacology & therapeutics

    (2006)
  • DG Blazer

    Psychiatry and the oldest old

    The American journal of psychiatry

    (2000)
  • JB Marshall et al.

    Cardiovascular effects of tricyclic antidepressant drugs: therapeutic usage, overdose, and management of complications

    American heart journal

    (1982)
  • HG Westenberg

    Pharmacology of antidepressants: selectivity or multiplicity ?

    The Journal of clinical psychiatry

    (1999)
  • SP Roose et al.

    Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure

    Journal of clinical psychopharmacology

    (1987)
  • J Kaufman et al.

    Comorbidity of mood and anxiety disorders

    Depression and anxiety

    (2000)
  • BM Ruf et al.

    The 5-HT1B receptor: a novel target for the pathophysiology of depression

    Current drug targets

    (2009)
  • Cited by (0)

    View full text